Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PET/CT Characterization of Treatment Resistance in Patients with Metastatic Prostate Cancer

Trial Status: active

This clinical trial examines medical imaging of lesions (sites of disease) caused by the spread of prostate cancer. Medical scans help in learning how well cancer treatments works to kill prostate cancer cells and allow doctors to plan better treatment. Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, that some cancers take up and can be seen with PET. CT utilizes x-rays that traverse body from the outside. Computed tomography (CT) images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. Using different types of medical imaging may help researchers assess how lesions from prostate cancer become resistant to second-generation androgen resistant-targeted therapy, and how the different types of imaging compare in that assessment.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.